Alpha-defensins secreted by dysplastic granulocytes inhibit the differentiation of monocytes in chronic myelomonocytic leukemia

Blood

Volumn 115, Issue 1, 2010, Pages 78-88

  Droin, Nathalie ^a,b   Jacquel, Arnaud ^a,b   Hendra, Jean Baptiste ^b,c,d   Racoeur, Cindy ^a,b   Truntzer, Caroline ^b,c,d   Pecqueur, Delphine ^b,c,d   Benikhlef, Naïma ^a,b   Ciudad, Marion ^a,b   Guery, Leslie ^a,b   Jooste, Valérie ^a,b   Dufour, Erick ^a,b   Fenaux, Pierre ^e,f   Quesnel, Bruno ^g   Kosmider, Olivier ^h,i,j   Fontenay, Michaëla ^h,i,j   Ducoroy, Patrick ^a,b,c   Solary, Eric ^a,b,c,i  

^a Chu   (France)

^b UNIVERSITÉ DE BOURGOGNE   (France)

^c DIJON UNIVERSITY HOSPITAL   (France)

^d CENTRE GEORGES FRANÇOIS LECLERC   (France)

^e UNIVERSITÉ PARIS 13   (France)

^f Institut Gustave Roussy   (France)

^g LILLE UNIVERSITY HOSPITAL   (France)

^h Inserm U567 ^*  (France)

ⁱ INSERM   (France)

^j UNIVERSITÉ PARIS DESCARTES   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA DEFENSIN; ALPHA DEFENSIN 1; ALPHA DEFENSIN 2; ALPHA DEFENSIN 3; CD14 ANTIGEN; CD24 ANTIGEN; COLONY STIMULATING FACTOR 1; PROTEOME; PURINERGIC P2Y6 RECEPTOR; SURAMIN; UNCLASSIFIED DRUG; URIDINE DIPHOSPHATE; URIDINE TRIPHOSPHATE; CYTOKINE; PURINERGIC P2 RECEPTOR;

ARTICLE; BLOOD; CELL DIFFERENTIATION; CELL HETEROGENEITY; CHRONIC MYELOMONOCYTIC LEUKEMIA; CONTROLLED STUDY; GRANULOCYTE; HUMAN; HUMAN CELL; MONOCYTE; PHENOTYPE; PRIORITY JOURNAL; BIOSYNTHESIS; CYTOLOGY; DRUG EFFECT; MACROPHAGE; METABOLISM; PATHOLOGY; SECRETION;

ALPHA-DEFENSINS; ANTIGENS, CD14; ANTIGENS, CD24; CELL DIFFERENTIATION; CYTOKINES; GRANULOCYTES; HUMANS; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MACROPHAGE COLONY-STIMULATING FACTOR; MACROPHAGES; MONOCYTES; RECEPTORS, PURINERGIC P2; URIDINE DIPHOSPHATE; URIDINE TRIPHOSPHATE;

EID: 74949121616     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-05-224352     Document Type: Article

References (38)

1. Orazi A, Germing U. The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features. Leukemia. 2008; 22(7):1308-1319.
2. Dunbar AJ, Gondek LP, O'Keefe CL, et al. 250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. Cancer Res. 2008;68(24):10349-10357.
3. Jankowska AM, Szpurka H, Tiu RV, et al. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood. 2009;113(25):6403-6410.
4. Gelsi-Boyer V, Trouplin V, Adelaide J, et al. Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes. BMC Cancer. 2008;8:299.
5. Tyner JW, Erickson H, Deininger MW, et al. High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients. Blood. 2009;113(8):1749-1755.
6. Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers. N Engl J Med. 2009;360(22):2289-2301.
7. Lee BH, Tothova Z, Levine RL, et al. FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia. Cancer Cell. 2007;12(4):367-380.
8. Bellamy WT, Richter L, Sirjani D, et al. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood. 2001;97(5): 1427-1434.
9. Marcondes AM, Mhyre AJ, Stirewalt DL, Kim SH, Dinarello CA, Deeg HJ. Dysregulation of IL-32 in myelodysplastic syndrome and chronic myelomonocytic leukemia modulates apoptosis and impairs NK function. Proc Natl Acad Sci U S A. 2008;105(8):2865-2870.
10. Kotecha N, Flores NJ, Irish JM, et al. Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates. Cancer Cell. 2008;14(4):335-343.
11. Rébé C, Cathelin S, Launay S, et al. Caspase-8 prevents sustained activation of NF-kappaB in monocytes undergoing macrophagic differentiation. Blood. 2007;109(4):1442-1450.
12. Smyth GK, Michaud J, Scott HS. Use of within-array replicate spots for assessing differential expression in microarray experiments. Bioinformatics. 2005;21(9):2067-2075.
13. Khine AA, Del Sorbo L, Vaschetto R, et al. Human neutrophil peptides induce interleukin-8 production through the P2Y6 signaling pathway. Blood. 2006;107(7):2936-2942.
14. Bonifer C, Hoogenkamp M, Krysinska H, Tagoh H. How transcription factors program chromatin: lessons from studies of the regulation of myeloid-specific genes. Semin Immunol. 2008;20(4):257-263.
15. Chaly YV, Paleolog EM, Kolesnikova TS, Tikhonov II, Petratchenko EV, Voitenok NN. Neutrophil alpha-defensin human neutrophil peptide modulates cytokine production in human monocytes and adhesion molecule expression in endothelial cells. Eur Cytokine Netw. 2000;11(2):257-266.
16. Di Virgilio F, Chiozzi P, Ferrari D, et al. Nucleotide receptors: an emerging family of regulatory molecules in blood cells. Blood. 2001;97(3):587-600.
17. Koizumi S, Shigemoto-Mogami Y, Nasu-Tada K, et al. UDP acting at P2Y6 receptors is a mediator of microglial phagocytosis. Nature. 2007; 446(7139):1091-1095.
18. Bar I, Guns PJ, Metallo J, et al. Knockout mice reveal a role for P2Y6 receptor in macrophages, endothelial cells, and vascular smooth muscle cells. Mol Pharmacol. 2008;74(3):777-784.
19. Klotman ME, Chang TL. Defensins in innate antiviral immunity. Nat Rev Immunol. 2006;6(6):447-456.
20. Droin N, Hendra JB, Ducoroy P, Solary E. Human defensins as cancer biomarkers and antitumour molecules. J Proteomics. 2009;72(6):918-927.
21. Lehrer RI. Multispecific myeloid defensins. Curr Opin Hematol. 2007;14(1):16-21.
22. Herwig S, Su Q, Zhang W, Ma Y, Tempst P. Distinct temporal patterns of defensin mRNA regulation during drug-induced differentiation of human myeloid leukemia cells. Blood. 1996;87(1):350-364.
23. Ma Y, Su Q, Tempst P. Differentiation-stimulated activity binds an ETS-like, essential regulatory element in the human promyelocytic defensin-1 promoter. J Biol Chem. 1998;273(15):8727-8740.
24. Tsutsumi-Ishii Y, Hasebe T, Nagaoka I. Role of CCAAT/enhancer-binding protein site in transcription of human neutrophil peptide-1 and -3 defensin genes. J Immunol. 2000;164(6):3264-3273.
25. Bokarewa M, Tarkowski A. Human alpha-defensins neutralize fibrinolytic activity exerted by staphylokinase. Thromb Haemost. 2004;91(5):991-999.
26. Kim C, Gajendran N, Mittrucker HW, et al. Human alpha-defensins neutralize anthrax lethal toxin and protect against its fatal consequences. Proc Natl Acad Sci U S A. 2005;102(13):4830-4835.
27. Lichtenstein A, Ganz T, Selsted ME, Lehrer RI. In vitro tumor cell cytolysis mediated by peptide defensins of human and rabbit granulocytes. Blood. 1986;68(6):1407-1410.
28. Barker E, Reisfeld RA.Amechanism for neutrophil-mediated lysis of human neuroblastoma cells. Cancer Res. 1993;53(2):362-367.
29. Economopoulou M, Bdeir K, Cines DB, et al. Inhibition of pathologic retinal neovascularization by alpha-defensins. Blood. 2005;106(12):3831-3838.
30. Halder TM, Bluggel M, Heinzel S, Pawelec G, Meyer HE, Kalbacher H. Defensins are dominant HLA-DR-associated self-peptides from CD34(-) peripheral blood mononuclear cells of different tumor patients (plasmacytoma, chronic myeloid leukemia). Blood. 2000;95(9):2890-2896.
31. Thompson L, Turko I, Murad F. Mass spectrometry-based relative quantification of human neutrophil peptides 1, 2, and 3 from biological samples. Mol Immunol. 2006;43(9):1485-1489.
32. Zhou L, Huang LQ, Beuerman RW, et al. Proteomic analysis of human tears: defensin expression after ocular surface surgery. J Proteome Res. 2004;3(3):410-416.
33. Soehnlein O, Zernecke A, Eriksson EE, et al. Neutrophil secretion products pave the way for inflammatory monocytes. Blood. 2008;112(4): 1461-1471.
34. Chertov O, Ueda H, Xu LL, et al. Identification of human neutrophil-derived cathepsin G and azurocidin/CAP37 as chemoattractants for mononuclear cells and neutrophils. J Exp Med. 1997; 186(5):739-747.
35. Spencer LT, Paone G, Krein PM, Rouhani FN, Rivera-Nieves J, Brantly ML. Role of human neutrophil peptides in lung inflammation associated with alpha1-antitrypsin deficiency. Am J Physiol Lung Cell Mol Physiol. 2004;286(3):L514-520.
36. Appelberg R. Neutrophils and intracellular pathogens: beyond phagocytosis and killing. Trends Microbiol. 2007;15(2):87-92.
37. Soehnlein O, Kai-Larsen Y, Frithiof R, et al. Neutrophil primary granule proteins HBP and HNP1-3 boost bacterial phagocytosis by human and murine macrophages. J Clin Invest. 2008;118(10): 3491-3502.
38. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9(3):162-174.